AOLS (Aeolus Pharmaceuticals) Beta: -134.2398 (As of Jul. 01, 2026)


What is Aeolus Pharmaceuticals Beta?

Aeolus Pharmaceuticals AOLS Beta is -134.2398 as of Jul. 01, 2026.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-01), Aeolus Pharmaceuticals's Beta is -134.2398.


Aeolus Pharmaceuticals  (OTCPK:AOLS) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Aeolus Pharmaceuticals Beta Related Terms


Aeolus Pharmaceuticals Beta Historical Data

* Premium members only.

The historical data trend for Aeolus Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aeolus Pharmaceuticals Beta Chart

Aeolus Pharmaceuticals Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.73 1.96 1.95 1.45

Aeolus Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.21 1.45 1.62 2.34 2.17

AOLS vs RDGL, PCYN, YBAO: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aeolus Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aeolus Pharmaceuticals Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aeolus Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where Aeolus Pharmaceuticals's Beta falls into.



Aeolus Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -134.2398 mean?
Aeolus Pharmaceuticals (AOLS) has a Beta of -134.2398 as of Jul. 01, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Aeolus Pharmaceuticals and its competitors.
Is Aeolus Pharmaceuticals' Beta too high?
Aeolus Pharmaceuticals' current Beta is -134.2398.
How does Aeolus Pharmaceuticals' Beta compare to RDGL and PCYN?
Aeolus Pharmaceuticals' Beta of -134.2398 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Aeolus Pharmaceuticals and its competitors. Aeolus Pharmaceuticals's current Beta is -134.2398. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aeolus Pharmaceuticals stock overvalued right now?
Aeolus Pharmaceuticals (AOLS) has a current Beta of -134.2398. The current Beta is -134.2398. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Aeolus Pharmaceuticals (AOLS), the current Beta is -134.2398 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aeolus Pharmaceuticals Business Description

Address 26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.